2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.

# 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year. **Read the full article:** [CNBC](https://www.cnbc.com/2026/01/10/2026-is-the-year-of-obesity-pills-from-novo-nordisk-eli-lilly-.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*